Business
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Sept. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.\n\n \n \n \n \n \n \n\n \nCiti 18th Annual BioPharma ConferenceWednesday, September 6th, 2023 at 1:00 PM ET\nTargeted Oncology Panel participation by Paul Stone, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst.Morgan Stanley 21st Annual Global Healthcare ConferenceMonday, September 11th, 2023 at 10:40 AM ET\nFireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Ryuk Byun, MD, Executive Director.A live audio webcast of conference events, as permitted by conference host, will be available at the \"Investors/News and Events/Investor Calendar\" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.\nAbout IDEAYA Biosciences\nIDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. \nForward-Looking Statements\nThis press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-Q filed on August 10, 2023 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.\nInvestor and Media ContactIDEAYA Bioscience...